Literature DB >> 22586335

Cushing syndrome due to ritonavir-fluticasone interaction.

Eduardo Canalejo1, María S Pacheco.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22586335      PMCID： PMC3478357          DOI： 10.1503/cmaj.111315

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  3 in total

1.  Iatrogenic Cushing's syndrome due to coadministration of ritonavir and inhaled budesonide in an asthmatic human immunodeficiency virus infected patient.

Authors:  Eynat Kedem; Eduardo Shahar; Gamal Hassoun; Shimon Pollack
Journal:  J Asthma       Date:  2010-09       Impact factor: 2.515

Review 2.  Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature.

Authors:  M M Foisy; E M K Yakiwchuk; I Chiu; A E Singh
Journal:  HIV Med       Date:  2008-05-04       Impact factor: 3.180

Review 3.  Iatrogenic Cushing's syndrome in HIV-infected patients receiving ritonavir and inhaled fluticasone: description of 4 new cases and review of the literature.

Authors:  Nadia Valin; Nathalie De Castro; Valerie Garrait; Anne Bergeron; Clara Bouche; Jean Michel Molina
Journal:  J Int Assoc Physicians AIDS Care (Chic)       Date:  2009-03-06
  3 in total
  5 in total

1.  Exogenous steroid-induced hypoadrenalism in a person living with HIV caused by a drug-drug interaction between cobicistat and intrabursal triamcinolone.

Authors:  Navnit Makaram; Clark D Russell; Simon Benedict Roberts; Jarrad Stevens; Gavin Macpherson
Journal:  BMJ Case Rep       Date:  2018-12-14

2.  Pharmacist-led pre-treatment assessment, management and outcomes in a Hepatitis C treatment patient cohort.

Authors:  Miriam Coghlan; Aisling O'Leary; Gail Melanophy; Colm Bergin; Suzanne Norris
Journal:  Int J Clin Pharm       Date:  2019-07-11

3.  Influence of low-dose ritonavir with and without darunavir on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone.

Authors:  Sarita D Boyd; Colleen Hadigan; Maryellen McManus; Cheryl Chairez; Lynnette K Nieman; Alice K Pau; Raul M Alfaro; Joseph A Kovacs; Monica M Calderon; Scott R Penzak
Journal:  J Acquir Immune Defic Syndr       Date:  2013-07-01       Impact factor: 3.731

Review 4.  HIV-associated obstructive lung diseases: insights and implications for the clinician.

Authors:  M Bradley Drummond; Gregory D Kirk
Journal:  Lancet Respir Med       Date:  2014-05-13       Impact factor: 30.700

Review 5.  Efficacy of lopinavir-ritonavir combination therapy for the treatment of hospitalized COVID-19 patients: a meta-analysis.

Authors:  Jiawen Deng; Fangwen Zhou; Wenteng Hou; Kiyan Heybati; Saif Ali; Oswin Chang; Zachary Silver; Thanansayan Dhivagaran; Harikrishnaa Ba Ramaraju; Chi Yi Wong; Qi Kang Zuo; Elizabeth Lapshina; Madeline Mellett
Journal:  Future Virol       Date:  2022-01-31       Impact factor: 1.831
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.